Biomea Fusion (BMEA) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
OS Therapies (OSTX) has outperformed Biomea Fusion (BMEA) over the past year, losing 28.6% versus a loss of 42.5%. Biomea Fusion is the larger company by market cap ($62.8 million vs $61.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | OSTX |
|---|---|---|
| Share price | $0.8689 | $1.32 |
| Market cap | $62.82M | $61.78M |
| 1-day change | +3.89% | -6.38% |
| YTD return | -29.93% | -5.71% |
| 1-year return | -42.46% | -28.65% |
| 5-year return | -92.09% | — |
| Forward P/E | — | 3.81 |
| EPS (TTM) | $-0.29 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-61.80M | $-28.75M |
| 52-week high | $2.24 | $2.25 |
| 52-week low | $0.7995 | $1.15 |
| Distance from 52-week high | -61.16% | -41.33% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +705.62% | +543.94% |
| Average volume | 1.93M | 578.15K |
| Shares outstanding | 72.30M | 46.81M |
| Employees | 37 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSTX has outperformed BMEA by 13.8 percentage points over the past year.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
BMEA vs OSTX FAQ
Which is bigger, Biomea Fusion or OS Therapies?
Biomea Fusion (BMEA) is larger, with a market capitalization of $62.82M compared with $61.78M for OS Therapies (OSTX).
Which stock has performed better over the past year, BMEA or OSTX?
OSTX returned -28.65% over the past 12 months, compared with -42.46% for BMEA (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and OS Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.